HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NVS-CECR2-1

bromodomain inhibitor

Also Known As:

N-Cyclopropyl-2-(propylsulfonyl)-6-(1-(2,2,6,6-tetramethyl-4-piperidinyl)-1H-indol-5-yl)-4-pyrimidinamine; NVS-1

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - NVS-CECR2-1: 1
  - Piperidines: 17
    - NVS-CECR2-1: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - NVS-CECR2-1: 1

Experts

1.	Kwon, Jongbum: 1 article (10/2020)
2.	Lee, Daye: 1 article (10/2020)
3.	Lee, Shin-Ai: 1 article (10/2020)
4.	Park, Seul Gi: 1 article (10/2020)
5.	Seo, Hye-Ran: 1 article (10/2020)

Related Diseases

1.	Neoplasms (Cancer) 10/01/2020 - "This study reports for the first time the cancer cell cytotoxic activity for NVS-CECR2-1 and provides a possibility of this BRD inhibitor to be developed as an anticancer therapeutic agent." 10/01/2020 - "Interestingly, our data show that NVS-CECR2-1 also kills cancer cells by CECR2-independent mechanism. " 10/01/2020 - "The sensitivity of the cancer cells to NVS-CECR2-1 is reduced by CECR2 depletion, suggesting that NVS-CECR2-1 exerts its activity by targeting CECR2. " 10/01/2020 - "Cytotoxic activity of bromodomain inhibitor NVS-CECR2-1 on human cancer cells." 10/01/2020 - "NVS-CECR2-1 exhibits cytotoxic activity against various human cancer cells, killing SW48 colon cancer cells in particular with a submicromolar half maximum inhibition value mainly by inducing apoptosis. "
2.	Colonic Neoplasms (Colon Cancer) 10/01/2020 - "NVS-CECR2-1 exhibits cytotoxic activity against various human cancer cells, killing SW48 colon cancer cells in particular with a submicromolar half maximum inhibition value mainly by inducing apoptosis. "
3.	Schmid-Fraccaro syndrome 10/01/2020 - "Here, we investigated a potential anticancer activity of the recently developed non-BET family BRD inhibitor NVS-CECR2-1 that targets the cat eye syndrome chromosome region, candidate 2 (CECR2). "